Navigation Links
New nanoparticles target cardiovascular disease
Date:1/18/2010

CAMBRIDGE, Mass. Researchers at MIT and Harvard Medical School have built targeted nanoparticles that can cling to artery walls and slowly release medicine, an advance that potentially provides an alternative to drug-releasing stents in some patients with cardiovascular disease.

The particles, dubbed "nanoburrs" because they are coated with tiny protein fragments that allow them to stick to target proteins, can be designed to release their drug payload over several days. They are one of the first such particles that can precisely home in on damaged vascular tissue, says Omid Farokhzad, associate professor at Harvard Medical School and an author of a paper describing the nanoparticles in the Jan. 18 issue of the Proceedings of the National Academy of Sciences.

Farokhzad and MIT Institute Professor Robert Langer, also an author of the paper, have previously developed nanoparticles that seek out and destroy tumors.

The nanoburrs are targeted to a specific structure, known as the basement membrane, which lines the arterial walls and is only exposed when those walls are damaged. Therefore, the nanoburrs could be used to deliver drugs to treat atherosclerosis and other inflammatory cardiovascular diseases. In the current study, the team used paclitaxel, a drug that inhibits cell division and helps prevent the growth of scar tissue that can clog arteries.

"This is a very exciting example of nanotechnology and cell targeting in action that I hope will have broad ramifications," says Langer.

The researchers hope the particles could become a complementary approach that can be used with vascular stents, which are the standard of care for most cases of clogged and damaged arteries, or in lieu of stents in areas not well suited to them, such as near a fork in the artery.

The particles, which are spheres 60 nanometers in diameter, consist of three layers: an inner core containing a complex of the drug and a polym
'/>"/>

Contact: Jen Hirsch
jfhirsch@mit.edu
617-253-1682
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2

Related biology news :

1. First metallic nanoparticles resistant to extreme heat
2. Small nanoparticles bring big improvement to medical imaging
3. Nanoparticles used in common household items caused genetic damage in mice
4. Behavior modification could ease concerns about nanoparticles
5. Knocking nanoparticles off the socks
6. Clemson bioengineer uses nanoparticles to target drugs
7. Therapeutic nanoparticles give new meaning to sugar-coating medicine
8. Carbon nanoparticles toxic to adult fruit flies but benign to young
9. New insights into health and environmental effects of carbon nanoparticles
10. Facile synthesis of nanoparticles with multiple functions advanced in Singapore
11. University of Leicester researchers discover new fluorescent silicon nanoparticles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2014)... 2014   Marvin Test Solutions , a ... for military, aerospace, and manufacturing organizations, today announced ... TS-900 PXI semiconductor test platform . The ... systems to customers at a fraction of the ... ATE. "Our semiconductor customers asked ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws against ... are piloting the North American and European automotive sector ... growing, gesture recognition systems that are intuitive and able ... in the industry. New analysis from ... Recognition Market in Europe and ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... clumps of protein found within nerve cells are ... were first identified in the early 1900s by German ... in a protein called tau cause it to aggregate ... Normally, the tau protein is involved in the formation ...
... in the mainland United States known for its tropical smell now ... house ants - so called because they tend to invade houses ... to Hawaii. And, according to Purdue University entomologist Grzegorz Buczkowski, it ... "Odorous house ants in Hawaii are not like they are ...
... Mich. Discovering new treatments and battling dangerous infections ... targeting the genetic disorder cystic fibrosis with projects funded ... studies, with support from a $110,000 grant from Hunt ... Translational Sciences Institute, expand the relationship between the two ...
Cached Biology News:Chemical engineers help decipher mystery of neurofibrillary tangle formation in Alzheimer's brains 2Pesky ants found in Hawaii demonstrate invasive characteristics 24 projects target cystic fibrosis with Hunt for a Cure funds 2
(Date:12/24/2014)... Nashville, Tenn. (PRWEB) December 23, 2014 ... Hill was elected treasurer for the American Society ... to advancing knowledge and research in reproductive medicine. ... fills a seat on the executive board and will ... , Dr. Hill has actively supported ASRM since ...
(Date:12/24/2014)... , December 23, 2014 PharmaBoardroom,s ... , out today and available for free download , ... driving change and growth in the sector today. ... notable successes has been in developing a homegrown pharmaceutical manufacturing ... local production still remains some way off. A cursory comparison ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... 28 XTL Biopharmaceuticals,Ltd. (NASDAQ: XTLB ; ... the acquisition, development and commercialization of,therapeutics for the ... hepatitis C, today announced the receipt on August ... that, according to the,Company,s financial statements for the ...
... Compounds ... in Merck KGaA Pipeline, ... and development company, announced today that,it will collaborate with Merck ... applications for drug candidates. KineMed,s,proprietary pathway-based drug discovery and development ...
... IVD Revenue Exceeded HIFU Revenue ... FY2007 Annual Targets Under ... Inc. (the "Company") (Nasdaq: CMED ), a leading ... in-,vitro diagnostic products and high intensity focused ultrasound tumor,therapy ...
Cached Biology Technology:XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market 2XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market 3KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates 2China Medical Technologies Reports First Quarter Financial Results 2China Medical Technologies Reports First Quarter Financial Results 3China Medical Technologies Reports First Quarter Financial Results 4China Medical Technologies Reports First Quarter Financial Results 5China Medical Technologies Reports First Quarter Financial Results 6China Medical Technologies Reports First Quarter Financial Results 7China Medical Technologies Reports First Quarter Financial Results 8China Medical Technologies Reports First Quarter Financial Results 9China Medical Technologies Reports First Quarter Financial Results 10China Medical Technologies Reports First Quarter Financial Results 11China Medical Technologies Reports First Quarter Financial Results 12China Medical Technologies Reports First Quarter Financial Results 13China Medical Technologies Reports First Quarter Financial Results 14
... to ATP-binding proteins. To create this ... was linked through the Gamma-thiol of ... use for binding studies the BODIPY ... new substrate for Fhit a member ...
... Using information-rich MSn data, the ... of multiple levels of fragmentation, isotope ... techniques to accurately determine the correct ... Traditional approaches for deducing empirical formulae ...
... custom peptide synthesis with a wide variety of ... your research needs. Purity: IG(>50%), ... 2mg-1g Sequence Length: Up to ... N-acetylation, C-amidation, phosphorylation, D-amino acids, MAPs, KLH/BSA conjugation, ...
... 50 mg/L streptomycin sulfate, 100 mg/L kanamycin ... magnesium chloride. The use of a balanced ... generally attributed to early workers in the ... solution of inorganic salts designed to maintain ...
Biology Products: